Chugai Pharmaceutical (CHGCY) Stock Price, News & Analysis

Company Overview

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Key Stats

• Today's Range: $26.04 to $27.45
• 50-Day Range: $21.89 to $30.18
• 52-Week Range: $14.52 to $31.26
• Volume: 103,480 shs
• Average Volume: 198,412 shs
• Market Capitalization: $87.31 billion
• P/E Ratio: 34.45
• Dividend Yield: 0.94%
• Price Target: N/A
• Consensus Rating: N/A

Chugai Pharmaceutical Stock Analysis - MarketRank™

Chugai Pharmaceutical scored higher than 17% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Chugai Pharmaceutical.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: 5.41%

Earnings Growth

Earnings for Chugai Pharmaceutical are expected to grow by 5.41% in the coming year, from $0.74 to $0.78 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Chugai Pharmaceutical is 34.45, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.87.

Price to Earnings Ratio vs. Sector

The P/E ratio of Chugai Pharmaceutical is 34.45, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.92.

Price to Book Value per Share Ratio

Chugai Pharmaceutical has a P/B Ratio of 6.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chugai Pharmaceutical has recently decreased by 32.32%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Chugai Pharmaceutical pays a meaningful dividend of 1.01%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Chugai Pharmaceutical does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Chugai Pharmaceutical is 30.86%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Chugai Pharmaceutical will have a dividend payout ratio of 32.05% next year. This indicates that Chugai Pharmaceutical will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.00% of the outstanding shares of Chugai Pharmaceutical have been sold short.

Short Interest Ratio / Days to Cover

Chugai Pharmaceutical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Chugai Pharmaceutical has recently decreased by 32.32%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Chugai Pharmaceutical this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Chugai Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.01% of the stock of Chugai Pharmaceutical is held by institutions.

CHGCY Stock Analysis - Frequently Asked Questions

How have CHGCY shares performed this year?

Chugai Pharmaceutical's stock was trading at $21.97 at the start of the year. Since then, CHGCY shares have increased by 20.8% and is now trading at $26.53.
View the best growth stocks for 2025 here.

How were Chugai Pharmaceutical's earnings last quarter?

Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY) posted its earnings results on Thursday, April, 24th. The company reported $0.19 EPS for the quarter. The firm had revenue of $1.89 billion for the quarter. Chugai Pharmaceutical had a net margin of 33.07% and a trailing twelve-month return on equity of 21.53%.

How do I buy shares of Chugai Pharmaceutical?

Shares of CHGCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 4/24/2025
• Today: 5/28/2025
• Next Earnings (Estimated): 7/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Drugs, proprietaries, & sundries
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:CHGCY
• CIK: 1453934
• Web: www.chugai-pharm.co.jp
• Phone: (133) 281-6611
• Fax: N/A
• Employees: 7,604
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.81
• Trailing P/E Ratio: 34.45
• Forward P/E Ratio: 35.85
• P/E Growth: N/A
• Net Income: $2.56 billion
• Net Margins: 33.07%
• Pretax Margin: 46.39%
• Return on Equity: 21.53%
• Return on Assets: 18.63%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.53
• Quick Ratio: 4.70

Sales & Book Value

• Annual Sales: $7.74 billion
• Price / Sales: 11.28
• Cash Flow: $0.91 per share
• Price / Cash Flow: 29.01
• Book Value: $3.81 per share
• Price / Book: 6.96

Miscellaneous

• Outstanding Shares: 3,291,028,000
• Free Float: N/A
• Market Cap: $87.31 billion
• Optionable: Not Optionable
• Beta: 0.76